巻号一覧
45 巻, 8 号
選択された号の論文の5件中1～5を表示しています
- |<
- <
- 1
- >
- >|
-
束村 道雄1970 年 45 巻 8 号 p. 237-240
発行日: 1970年
公開日: 2011/05/24
ジャーナル フリーPathogenic scotochromogens (Group II), M. scrofulaceum and M. xenopei, and pathogenic nonphotochromogens (Group III), M. avium and M. intracellulare, were resistant to ethambutol, whereas nonpathogenic scotochromogens, tap water scotochromogens and M. fiavescens and nonpathogenic nonphotochromogens, M. nonchromogenicum, M. terrae, M. triviale, M. novum and M. gastri, were susceptible to ethambutol.
The susceptibility to ethambutol was determined by a simple method such as inoculating one loopful of the test organism to the Ogawa's egg medium containing 5 μg/ml ethambutol and comparing the growth on the ethambutol medium with growth on the control medium (Ogawa's egg medium containing no agent). By comparison with the growth on the control medium, no growth or, if any, scant growth (much less than the growth on the control medium)on the ethambutol medium was read as “negative growth” after incubation at 37°C for 2 weeks.抄録全体を表示PDF形式でダウンロード (436K) -
結核療法研究協議会1970 年 45 巻 8 号 p. 241-250
発行日: 1970年
公開日: 2011/05/24
ジャーナル フリーThis study was made to clarify the present status of surgical treatment for failures cases after operation and for cases with empyema, and the frequency of surgical procedures applied and the result of surgical treatment in recent years were discussed.
The material consisted of 726 cases who had undergone the operation in 1967 at 30 institutions belonging to the Tuberculosis Research Committee and had been observed for the period of at least 6 months postoperatively. These cases were divided into 172 failures cases after operation (Group A), 77 cases of empyema (Group B) and the remaining 1, 437 cases (Group C)which were considered as usual cases. In this study, the successful cases, negative sputum cases, unsuccessful cases and death cases were used to evaluate the result of surgical treatment, and their definition was similar to that used in our several previous reports.抄録全体を表示PDF形式でダウンロード (1274K) -
第1報予備的研究.重症耐性肺結核に対する治療成績堂野前 維摩郷, 藤田 真之助, 五味 二郎, 日比野 進, 宝来 善次, 伊藤 文雄, 岩崎 龍郎, 河盛 勇造, 北本 治, 長沢 潤, ...1970 年 45 巻 8 号 p. 251-256
発行日: 1970年
公開日: 2011/05/24
ジャーナル フリーBefore starting collaborative and controlled clinical trials for Rifampicin (abbrev. RFP), a preliminary study with RFP was carried out to investigate clinical effectiveness and side effects of the drug in 50 pulmonary tuberculosis patients with cavities and drug resistance. As indicated in Table 1, patients with a history of suffering from tuberculosis for more than five years occupied approximately 80% of the total cases, and the patients classified as far advanced by NTA classification amounted to 60%. All patients were culture positive and resistant to at least three of the conventional antituberculous drugs, and 24% of the patients were resistant to nine drugs. RFP was used in addition to the previous drug regimen and was administered for six months.450 mg of RFP were given orally once daily 30 minutes before breakfast.抄録全体を表示PDF形式でダウンロード (713K) -
第2報未治療肺結核に対するRFP・INH・PAS併用とSM・INH・PAS併用の治療効果比較堂野前 維摩郷, 藤田 真之助, 五味 二郎, 日比野 進, 宝来 善次, 伊藤 文雄, 岩崎 龍郎, 河盛 勇造, 北本 治, 長沢 潤, ...1970 年 45 巻 8 号 p. 257-262
発行日: 1970年
公開日: 2011/05/24
ジャーナル フリーThis study deals with the clinical effects of Rifampicin (RFP) -isoniazid (INH) . paraaminosalicylic acid (PAS) compared with streptomycin (SM)⋅INH⋅PAS in the treatment of original cases of pulmonary tuberculosis.
Inpatients with p ositive tubercle bacilli and/or cavities were allocated at random to one of the two regimens; 67 cases were included in the RFP⋅INH⋅PAS group and 64 cases in the SM. INH. PAS group, after exclusion of those who were discharged before completion of the th ree months treatment and one who had been proven as a primary drug resistant case.450 mg of RFP were given once daily, 1 g streptomycin twice weekly, 0.3g INH once daily and 10 g PAS daily in three divided dose after each meal. Both treatments were continued for six months. The background factors of cases in each group were almost similar. The clinical effects of the treatment were compared according to the rate of improvements of chest radiograms and bacilli conversion rate in sputa. Moderate or marked improvement of basic lesions on chest radiograms was observed in 26% after three months treatment and 53% after six months in the RFP group, while the rate was 18% after three months and 51% after six months in the SM group. The rate of moderate or marked improvement in the cavities with non-sclerotic wall after six months treatment were 34% in the RFP group and 27% in the SM group. The tubercle bacilli in sputa showed a negative conversion rate on culture in 98% after three months and 100%after six months by RFP⋅INH⋅PAS and in 84% and 95%, respectively, by SM. INH. PAS. The difference in the negative conversion rate on culture at three months in the far advanced cases was statistically significant at 5% level in favour of RFP⋅INII⋅PAS. The only side effect was allergic reactions such as fever and skin rash which were observed in one case of the RFP group and two cases of the SM group. It is concluded that RFP⋅INH⋅PAS is as good as, or may be better than SM⋅INH⋅PAS in the original treatment of pulmonary tuberculosis.抄録全体を表示PDF形式でダウンロード (672K) -
束村 道雄, 水野 松司, 山本 正彦1970 年 45 巻 8 号 p. 263-272
発行日: 1970年
公開日: 2011/05/24
ジャーナル フリーIn vitro and in vivo experimental studies were carried out on the antituberculous action of a new antibiotic, Lividomycin, discovered by the Kowa Company, Nagoya. Mycobacterium tuberculosis H37Rv, and Aoyama-B and tubercle bacilli recently isolated from sputa of patients were used in the study. The antibiotic is produced by Streptomyces lividus n. sp. and has a molecular formula C29H55N5018b elonging to the aminocyclitol group.抄録全体を表示PDF形式でダウンロード (1084K)
- |<
- <
- 1
- >
- >|